The CAR enhances anti-tumour activity against CD19 expressing B-cells, while the CD16 receptor increases ADCC (Zhu et al. 2020b), and the IL-15/IL-15r fusion receptor promotes in vivo persistence and expansion of the engineered iPSC-NK cells (Fujii et al. 2018). Here, IL15 is linked to neoplasm.